FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062515126> ?p ?o ?g. }

• W2062515126 endingPage "812" @default.
• W2062515126 startingPage "807" @default.
• W2062515126 abstract "To analyse the safety and efficacy of replacing the protease inhibitor (PI) by nevirapine (NVP) in subjects experiencing a long-term control of virus replication under a triple PI-containing antiretroviral combination.Prospective evaluation of 138 HIV-positive subjects with plasma viral load below 50 HIV-RNA copies/ml for the last 6 months under a triple PI-containing regimen, who were randomly assigned to either replace the PI by NVP (n = 104) or continue on the same treatment (n = 34).Viral load, CD4 count, lipid profile, body-shape features, and quality of life parameters were all assessed at the time of randomization and every 3 months thereafter.In an intent-to-treat analysis, a rebound in viral load occurred in 11% of subjects during the first 6 months after replacing the PI by NVP, whereas it appeared in 29% of those who remained on PI (P = 0.007). Treatment failure was related to lack of adherence in 90% of subjects on PI, but only in 22% of those receiving NVP (P = 0.006). The CD4 cell count outcome did not differ significantly comparing both groups at 6 months, although in patients receiving NVP an average reduction of 35 x 10(6) cells/l was observed, whereas in those on PI a positive trend was still recorded (+54 x 10(6) cells/l). At the time of randomization, 77.5 and 57.5% of subjects had cholesterol and triglyceride values above 200 mg/dl, respectively. No significant changes in the lipid profile were observed in any of the groups thereafter. Body-shape abnormalities were recorded in 70% of persons at the time of randomization, and partially reversed at 6 months in 50% of subjects who replaced the PI by NVP. A quality of life score recorded a significant improvement in subjects who switched to NVP compared with those who continued on PI.The replacement of PI by NVP seems to be safe both virologically and immunologically, provides a significant improvement in the quality of life and in half of patients ameliorate lipodystrophic body-shape changes at 6 months, although serum lipid abnormalities still remain unmodified." @default.
• W2062515126 created "2016-06-24" @default.
• W2062515126 creator A5003553956 @default.
• W2062515126 creator A5009751300 @default.
• W2062515126 creator A5019811024 @default.
• W2062515126 creator A5068063061 @default.
• W2062515126 creator A5074827235 @default.
• W2062515126 creator A5076951981 @default.
• W2062515126 date "2000-05-01" @default.
• W2062515126 modified "2023-09-27" @default.
• W2062515126 title "Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy" @default.
• W2062515126 cites W1963945715 @default.
• W2062515126 cites W1971270312 @default.
• W2062515126 cites W1978444406 @default.
• W2062515126 cites W1989041073 @default.
• W2062515126 cites W2027812093 @default.
• W2062515126 cites W2034660792 @default.
• W2062515126 cites W2041363786 @default.
• W2062515126 cites W2044139946 @default.
• W2062515126 cites W2065220464 @default.
• W2062515126 cites W2092398687 @default.
• W2062515126 cites W2099352670 @default.
• W2062515126 cites W2105912359 @default.
• W2062515126 cites W2122204312 @default.
• W2062515126 cites W2142144836 @default.
• W2062515126 cites W2153683121 @default.
• W2062515126 cites W2160676835 @default.
• W2062515126 cites W2313623892 @default.
• W2062515126 cites W2324473093 @default.
• W2062515126 cites W2337376130 @default.
• W2062515126 cites W4248142985 @default.
• W2062515126 cites W4250396005 @default.
• W2062515126 doi "https://doi.org/10.1097/00002030-200005050-00006" @default.
• W2062515126 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10839588" @default.
• W2062515126 hasPublicationYear "2000" @default.
• W2062515126 type Work @default.
• W2062515126 sameAs 2062515126 @default.
• W2062515126 citedByCount "168" @default.
• W2062515126 countsByYear W20625151262012 @default.
• W2062515126 countsByYear W20625151262013 @default.
• W2062515126 countsByYear W20625151262014 @default.
• W2062515126 countsByYear W20625151262015 @default.
• W2062515126 countsByYear W20625151262016 @default.
• W2062515126 countsByYear W20625151262017 @default.
• W2062515126 countsByYear W20625151262022 @default.
• W2062515126 crossrefType "journal-article" @default.
• W2062515126 hasAuthorship W2062515126A5003553956 @default.
• W2062515126 hasAuthorship W2062515126A5009751300 @default.
• W2062515126 hasAuthorship W2062515126A5019811024 @default.
• W2062515126 hasAuthorship W2062515126A5068063061 @default.
• W2062515126 hasAuthorship W2062515126A5074827235 @default.
• W2062515126 hasAuthorship W2062515126A5076951981 @default.
• W2062515126 hasConcept C126322002 @default.
• W2062515126 hasConcept C142462285 @default.
• W2062515126 hasConcept C159047783 @default.
• W2062515126 hasConcept C168563851 @default.
• W2062515126 hasConcept C181199279 @default.
• W2062515126 hasConcept C203014093 @default.
• W2062515126 hasConcept C204243189 @default.
• W2062515126 hasConcept C2776714187 @default.
• W2062515126 hasConcept C2778163477 @default.
• W2062515126 hasConcept C2778913445 @default.
• W2062515126 hasConcept C2779130552 @default.
• W2062515126 hasConcept C2781143361 @default.
• W2062515126 hasConcept C2781413609 @default.
• W2062515126 hasConcept C2993143319 @default.
• W2062515126 hasConcept C3013748606 @default.
• W2062515126 hasConcept C55493867 @default.
• W2062515126 hasConcept C71924100 @default.
• W2062515126 hasConcept C86803240 @default.
• W2062515126 hasConcept C90924648 @default.
• W2062515126 hasConceptScore W2062515126C126322002 @default.
• W2062515126 hasConceptScore W2062515126C142462285 @default.
• W2062515126 hasConceptScore W2062515126C159047783 @default.
• W2062515126 hasConceptScore W2062515126C168563851 @default.
• W2062515126 hasConceptScore W2062515126C181199279 @default.
• W2062515126 hasConceptScore W2062515126C203014093 @default.
• W2062515126 hasConceptScore W2062515126C204243189 @default.
• W2062515126 hasConceptScore W2062515126C2776714187 @default.
• W2062515126 hasConceptScore W2062515126C2778163477 @default.
• W2062515126 hasConceptScore W2062515126C2778913445 @default.
• W2062515126 hasConceptScore W2062515126C2779130552 @default.
• W2062515126 hasConceptScore W2062515126C2781143361 @default.
• W2062515126 hasConceptScore W2062515126C2781413609 @default.
• W2062515126 hasConceptScore W2062515126C2993143319 @default.
• W2062515126 hasConceptScore W2062515126C3013748606 @default.
• W2062515126 hasConceptScore W2062515126C55493867 @default.
• W2062515126 hasConceptScore W2062515126C71924100 @default.
• W2062515126 hasConceptScore W2062515126C86803240 @default.
• W2062515126 hasConceptScore W2062515126C90924648 @default.
• W2062515126 hasIssue "7" @default.
• W2062515126 hasLocation W20625151261 @default.
• W2062515126 hasLocation W20625151262 @default.
• W2062515126 hasOpenAccess W2062515126 @default.
• W2062515126 hasPrimaryLocation W20625151261 @default.
• W2062515126 hasRelatedWork W2001009580 @default.
• W2062515126 hasRelatedWork W2048864317 @default.
• W2062515126 hasRelatedWork W2095332267 @default.

• next